Stay updated with breaking news from Markd Eisner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vir Biotechnology, Inc. announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer , effective June 03, 2024. Dr. Eisner will be a part of...
SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Oct 13, 2023--
Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointments of Joseph R. Arron, M.D., Ph.D., as Chief...
FibroGen joins Illumina and Genentech in implementing job cuts among Bay Area biotech firms this year.
- Study did not meet the primary endpoint- Pamrevlumab was generally safe and well tolerated- ZEPHYRUS-2 Phase 3 study will be discontinued- Company to implement plan to extend cash runway into 2026 SAN FRANCISCO, June 26, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline results from its Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). The study compared treatment with pamrevlumab to pla